XOMA CORP.PRF.SH.SER.A 25
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential… Read more
Market Cap & Net Worth: XOMA CORP.PRF.SH.SER.A 25 (X0M)
XOMA CORP.PRF.SH.SER.A 25 (F:X0M) has a market capitalization of $198.51K (€193.39K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #14870 globally and #1536 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XOMA CORP.PRF.SH.SER.A 25's stock price €21.00 by its total outstanding shares 9209 (9.21K).
XOMA CORP.PRF.SH.SER.A 25 Market Cap History: 2021 to 2026
XOMA CORP.PRF.SH.SER.A 25's market capitalization history from 2021 to 2026. Data shows growth from $167.09K to $198.51K (8.19% CAGR).
XOMA CORP.PRF.SH.SER.A 25 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XOMA CORP.PRF.SH.SER.A 25's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of X0M by Market Capitalization
Companies near XOMA CORP.PRF.SH.SER.A 25 in the global market cap rankings as of March 19, 2026.
Key companies related to XOMA CORP.PRF.SH.SER.A 25 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
XOMA CORP.PRF.SH.SER.A 25 Historical Marketcap From 2021 to 2026
Between 2021 and today, XOMA CORP.PRF.SH.SER.A 25's market cap moved from $167.09K to $ 198.51K, with a yearly change of 8.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €198.51K | -4.55% |
| 2025 | €207.96K | -10.57% |
| 2024 | €232.54K | +18.44% |
| 2023 | €196.33K | +9.28% |
| 2022 | €179.66K | +7.53% |
| 2021 | €167.09K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of XOMA CORP.PRF.SH.SER.A 25 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $198.51K USD |
| MoneyControl | $198.51K USD |
| MarketWatch | $198.51K USD |
| marketcap.company | $198.51K USD |
| Reuters | $198.51K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.